nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—CYP1A1—Riluzole—amyotrophic lateral sclerosis	0.517	0.691	CbGbCtD
Dapagliflozin—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.231	0.309	CbGbCtD
Dapagliflozin—Angina unstable—Riluzole—amyotrophic lateral sclerosis	0.016	0.135	CcSEcCtD
Dapagliflozin—Vulvovaginal candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00767	0.065	CcSEcCtD
Dapagliflozin—Vulvovaginal mycotic infection—Riluzole—amyotrophic lateral sclerosis	0.00737	0.0625	CcSEcCtD
Dapagliflozin—Lung disorder—Riluzole—amyotrophic lateral sclerosis	0.00569	0.0483	CcSEcCtD
Dapagliflozin—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.00434	0.0368	CcSEcCtD
Dapagliflozin—SLC5A11—medulla oblongata—amyotrophic lateral sclerosis	0.00397	0.117	CbGeAlD
Dapagliflozin—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00364	0.0309	CcSEcCtD
Dapagliflozin—SLC5A11—spinal cord—amyotrophic lateral sclerosis	0.00354	0.105	CbGeAlD
Dapagliflozin—Phlebitis—Riluzole—amyotrophic lateral sclerosis	0.0034	0.0288	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00336	0.0285	CcSEcCtD
Dapagliflozin—SLC5A4—nervous system—amyotrophic lateral sclerosis	0.00328	0.097	CbGeAlD
Dapagliflozin—SLC5A4—central nervous system—amyotrophic lateral sclerosis	0.00316	0.0934	CbGeAlD
Dapagliflozin—Thirst—Riluzole—amyotrophic lateral sclerosis	0.00307	0.0261	CcSEcCtD
Dapagliflozin—SLC5A11—nervous system—amyotrophic lateral sclerosis	0.00298	0.0881	CbGeAlD
Dapagliflozin—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00294	0.0249	CcSEcCtD
Dapagliflozin—SLC5A11—central nervous system—amyotrophic lateral sclerosis	0.00287	0.0848	CbGeAlD
Dapagliflozin—SLC5A11—cerebellum—amyotrophic lateral sclerosis	0.00281	0.0829	CbGeAlD
Dapagliflozin—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00272	0.0231	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.00267	0.0227	CcSEcCtD
Dapagliflozin—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00253	0.0214	CcSEcCtD
Dapagliflozin—SLC5A4—brain—amyotrophic lateral sclerosis	0.00251	0.0741	CbGeAlD
Dapagliflozin—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00246	0.0209	CcSEcCtD
Dapagliflozin—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00236	0.02	CcSEcCtD
Dapagliflozin—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00234	0.0198	CcSEcCtD
Dapagliflozin—SLC5A11—brain—amyotrophic lateral sclerosis	0.00228	0.0673	CbGeAlD
Dapagliflozin—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00225	0.0191	CcSEcCtD
Dapagliflozin—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00225	0.0191	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00222	0.0188	CcSEcCtD
Dapagliflozin—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00221	0.0187	CcSEcCtD
Dapagliflozin—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00219	0.0186	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.002	0.0169	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00199	0.0169	CcSEcCtD
Dapagliflozin—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00198	0.0168	CcSEcCtD
Dapagliflozin—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00176	0.0149	CcSEcCtD
Dapagliflozin—Back pain—Riluzole—amyotrophic lateral sclerosis	0.0017	0.0144	CcSEcCtD
Dapagliflozin—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00161	0.0136	CcSEcCtD
Dapagliflozin—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00152	0.0129	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00149	0.0126	CcSEcCtD
Dapagliflozin—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00148	0.0126	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00144	0.0122	CcSEcCtD
Dapagliflozin—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00144	0.0122	CcSEcCtD
Dapagliflozin—Infection—Riluzole—amyotrophic lateral sclerosis	0.00143	0.0121	CcSEcCtD
Dapagliflozin—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.0014	0.0118	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00139	0.0118	CcSEcCtD
Dapagliflozin—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00134	0.0114	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00124	0.0105	CcSEcCtD
Dapagliflozin—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00123	0.0104	CcSEcCtD
Dapagliflozin—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00114	0.00968	CcSEcCtD
Dapagliflozin—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00114	0.00964	CcSEcCtD
Dapagliflozin—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00898	CcSEcCtD
Dapagliflozin—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000951	0.00806	CcSEcCtD
Dapagliflozin—Rash—Riluzole—amyotrophic lateral sclerosis	0.000907	0.00769	CcSEcCtD
Dapagliflozin—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000906	0.00768	CcSEcCtD
Dapagliflozin—Headache—Riluzole—amyotrophic lateral sclerosis	0.000901	0.00764	CcSEcCtD
Dapagliflozin—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.000855	0.0252	CbGeAlD
Dapagliflozin—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000854	0.00724	CcSEcCtD
Dapagliflozin—CYP2A6—cerebellum—amyotrophic lateral sclerosis	0.000645	0.0191	CbGeAlD
Dapagliflozin—CYP2A6—brain—amyotrophic lateral sclerosis	0.000524	0.0155	CbGeAlD
Dapagliflozin—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.00049	0.0145	CbGeAlD
Dapagliflozin—ABCB1—embryo—amyotrophic lateral sclerosis	0.000384	0.0114	CbGeAlD
Dapagliflozin—CYP1A1—nervous system—amyotrophic lateral sclerosis	0.000355	0.0105	CbGeAlD
Dapagliflozin—CYP1A1—central nervous system—amyotrophic lateral sclerosis	0.000342	0.0101	CbGeAlD
Dapagliflozin—CYP1A1—brain—amyotrophic lateral sclerosis	0.000272	0.00802	CbGeAlD
Dapagliflozin—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000261	0.0077	CbGeAlD
Dapagliflozin—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000257	0.00758	CbGeAlD
Dapagliflozin—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000251	0.00741	CbGeAlD
Dapagliflozin—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000247	0.0073	CbGeAlD
Dapagliflozin—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000246	0.00725	CbGeAlD
Dapagliflozin—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000241	0.00713	CbGeAlD
Dapagliflozin—UGT1A9—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000232	0.00229	CbGpPWpGaD
Dapagliflozin—CYP1A1—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000225	0.00223	CbGpPWpGaD
Dapagliflozin—UGT2B7—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000223	0.00221	CbGpPWpGaD
Dapagliflozin—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000219	0.00647	CbGeAlD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000219	0.00217	CbGpPWpGaD
Dapagliflozin—CYP2D6—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000216	0.00214	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—GSR—amyotrophic lateral sclerosis	0.000215	0.00214	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—GSR—amyotrophic lateral sclerosis	0.000215	0.00214	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000204	0.00202	CbGpPWpGaD
Dapagliflozin—CYP2D6—brain—amyotrophic lateral sclerosis	0.000196	0.00579	CbGeAlD
Dapagliflozin—UGT2B7—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000196	0.00194	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.000194	0.00192	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000193	0.00191	CbGpPWpGaD
Dapagliflozin—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000185	0.00545	CbGeAlD
Dapagliflozin—CYP1A2—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000183	0.00181	CbGpPWpGaD
Dapagliflozin—UGT1A9—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000181	0.0018	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PLB1—amyotrophic lateral sclerosis	0.00018	0.00179	CbGpPWpGaD
Dapagliflozin—CYP2A6—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000179	0.00177	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—CST3—amyotrophic lateral sclerosis	0.000178	0.00177	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—CST3—amyotrophic lateral sclerosis	0.000178	0.00177	CbGpPWpGaD
Dapagliflozin—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000178	0.00525	CbGeAlD
Dapagliflozin—SLC5A1—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000177	0.00175	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000177	0.00175	CbGpPWpGaD
Dapagliflozin—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000174	0.00513	CbGeAlD
Dapagliflozin—SLC5A4—Disease—CASP9—amyotrophic lateral sclerosis	0.000171	0.0017	CbGpPWpGaD
Dapagliflozin—CYP2C9—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000168	0.00167	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—GSR—amyotrophic lateral sclerosis	0.000166	0.00165	CbGpPWpGaD
Dapagliflozin—UGT1A9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000159	0.00157	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.000158	0.00156	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000157	0.00156	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000157	0.00155	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—CASP9—amyotrophic lateral sclerosis	0.000155	0.00154	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000153	0.00152	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000152	0.00151	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00015	0.00148	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00015	0.00148	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.00015	0.00148	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—ERBB4—amyotrophic lateral sclerosis	0.000146	0.00145	CbGpPWpGaD
Dapagliflozin—CYP1A2—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000144	0.00142	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000144	0.00142	CbGpPWpGaD
Dapagliflozin—CYP2A6—Fluoropyrimidine Activity—TP53—amyotrophic lateral sclerosis	0.000141	0.0014	CbGpPWpGaD
Dapagliflozin—ABCB1—brain—amyotrophic lateral sclerosis	0.000141	0.00417	CbGeAlD
Dapagliflozin—CYP2A6—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.00014	0.00138	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000137	0.00136	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—CHAT—amyotrophic lateral sclerosis	0.000137	0.00135	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	0.000136	0.00135	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000134	0.00132	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.00013	0.00129	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—CASP9—amyotrophic lateral sclerosis	0.00013	0.00128	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—CASP9—amyotrophic lateral sclerosis	0.00013	0.00128	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000127	0.00126	CbGpPWpGaD
Dapagliflozin—CYP1A1—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000127	0.00126	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000126	0.00124	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000125	0.00124	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—CD40LG—amyotrophic lateral sclerosis	0.000125	0.00124	CbGpPWpGaD
Dapagliflozin—CYP2A6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000122	0.00121	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000122	0.00121	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000122	0.00121	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—FIG4—amyotrophic lateral sclerosis	0.00012	0.00119	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000117	0.00116	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000115	0.00114	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000114	0.00113	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—APOE—amyotrophic lateral sclerosis	0.000113	0.00112	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000111	0.0011	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—ERBB4—amyotrophic lateral sclerosis	0.000111	0.0011	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—ERBB4—amyotrophic lateral sclerosis	0.000111	0.0011	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—C3—amyotrophic lateral sclerosis	0.00011	0.00109	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000108	0.00108	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—DAO—amyotrophic lateral sclerosis	0.000108	0.00107	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000107	0.00106	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	0.000107	0.00106	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000105	0.00104	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000104	0.00103	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.0001	0.000994	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.0001	0.000992	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	9.96e-05	0.000987	CbGpPWpGaD
Dapagliflozin—CYP1A2—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	9.95e-05	0.000986	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	9.91e-05	0.000982	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—FIG4—amyotrophic lateral sclerosis	9.73e-05	0.000965	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.51e-05	0.000942	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.51e-05	0.000942	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—APOE—amyotrophic lateral sclerosis	9.49e-05	0.00094	CbGpPWpGaD
Dapagliflozin—CYP2C9—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	9.48e-05	0.000939	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—VAPB—amyotrophic lateral sclerosis	9.39e-05	0.00093	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—TPK1—amyotrophic lateral sclerosis	9.39e-05	0.00093	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	9.37e-05	0.000928	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	9.16e-05	0.000907	CbGpPWpGaD
Dapagliflozin—CYP1A1—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	9.13e-05	0.000904	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	9.04e-05	0.000896	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	9e-05	0.000892	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—DAO—amyotrophic lateral sclerosis	8.8e-05	0.000872	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.74e-05	0.000866	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.74e-05	0.000866	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	8.66e-05	0.000858	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	8.6e-05	0.000853	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—APOE—amyotrophic lateral sclerosis	8.58e-05	0.000851	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—APOE—amyotrophic lateral sclerosis	8.58e-05	0.000851	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—VAPA—amyotrophic lateral sclerosis	8.58e-05	0.000851	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	8.51e-05	0.000844	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PLB1—amyotrophic lateral sclerosis	8.21e-05	0.000814	CbGpPWpGaD
Dapagliflozin—CYP1A2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	8.1e-05	0.000803	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	8e-05	0.000793	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.98e-05	0.000791	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—PTGS2—amyotrophic lateral sclerosis	7.76e-05	0.000769	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	7.65e-05	0.000759	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—GSR—amyotrophic lateral sclerosis	7.58e-05	0.000751	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—FIG4—amyotrophic lateral sclerosis	7.5e-05	0.000744	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.34e-05	0.000728	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—APOE—amyotrophic lateral sclerosis	7.19e-05	0.000712	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—APOE—amyotrophic lateral sclerosis	7.19e-05	0.000712	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—VAPB—amyotrophic lateral sclerosis	6.99e-05	0.000693	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—TPK1—amyotrophic lateral sclerosis	6.99e-05	0.000693	CbGpPWpGaD
Dapagliflozin—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	6.87e-05	0.000681	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	6.82e-05	0.000676	CbGpPWpGaD
Dapagliflozin—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	6.81e-05	0.000675	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—DAO—amyotrophic lateral sclerosis	6.79e-05	0.000672	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	6.77e-05	0.000671	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.75e-05	0.000669	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	6.72e-05	0.000666	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PLB1—amyotrophic lateral sclerosis	6.67e-05	0.000661	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	6.53e-05	0.000647	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	6.52e-05	0.000646	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.5e-05	0.000644	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	6.45e-05	0.000639	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	6.42e-05	0.000636	CbGpPWpGaD
Dapagliflozin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	6.4e-05	0.000634	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—VAPA—amyotrophic lateral sclerosis	6.4e-05	0.000634	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—CHAT—amyotrophic lateral sclerosis	6.22e-05	0.000617	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	6.16e-05	0.00061	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—GSR—amyotrophic lateral sclerosis	6.16e-05	0.00061	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.95e-05	0.000589	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—PTGS2—amyotrophic lateral sclerosis	5.88e-05	0.000583	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—PTGS2—amyotrophic lateral sclerosis	5.88e-05	0.000583	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	5.82e-05	0.000577	CbGpPWpGaD
Dapagliflozin—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	5.82e-05	0.000577	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	5.74e-05	0.000569	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	5.61e-05	0.000556	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—FIG4—amyotrophic lateral sclerosis	5.59e-05	0.000554	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	5.59e-05	0.000554	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	5.59e-05	0.000554	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—APOE—amyotrophic lateral sclerosis	5.55e-05	0.00055	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	5.54e-05	0.000549	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	5.49e-05	0.000544	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	5.26e-05	0.000522	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	5.26e-05	0.000522	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	5.22e-05	0.000517	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	5.22e-05	0.000517	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PLB1—amyotrophic lateral sclerosis	5.14e-05	0.00051	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	5.11e-05	0.000506	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—DAO—amyotrophic lateral sclerosis	5.06e-05	0.000501	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CHAT—amyotrophic lateral sclerosis	5.06e-05	0.000501	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	4.95e-05	0.000491	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	4.95e-05	0.000491	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.93e-05	0.000488	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.93e-05	0.000488	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	4.87e-05	0.000482	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	4.81e-05	0.000477	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	4.77e-05	0.000473	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.75e-05	0.000471	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GSR—amyotrophic lateral sclerosis	4.75e-05	0.00047	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	4.61e-05	0.000457	CbGpPWpGaD
Dapagliflozin—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	4.49e-05	0.000445	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.48e-05	0.000443	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	4.47e-05	0.000442	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	4.46e-05	0.000442	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	4.46e-05	0.000442	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.44e-05	0.00044	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	4.43e-05	0.000439	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	4.41e-05	0.000437	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	4.21e-05	0.000417	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	4.19e-05	0.000415	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	4.17e-05	0.000413	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	4.16e-05	0.000412	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	4.08e-05	0.000404	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	4.04e-05	0.0004	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CHAT—amyotrophic lateral sclerosis	3.9e-05	0.000386	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PLB1—amyotrophic lateral sclerosis	3.83e-05	0.00038	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	3.81e-05	0.000377	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.8e-05	0.000377	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.79e-05	0.000376	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	3.77e-05	0.000374	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	3.56e-05	0.000353	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSR—amyotrophic lateral sclerosis	3.54e-05	0.00035	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	3.47e-05	0.000344	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	3.44e-05	0.000341	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	3.44e-05	0.000341	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.34e-05	0.000331	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	3.22e-05	0.000319	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	3.22e-05	0.000319	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.22e-05	0.000319	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.16e-05	0.000313	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	3.15e-05	0.000312	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.07e-05	0.000305	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	3.06e-05	0.000303	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.93e-05	0.00029	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CHAT—amyotrophic lateral sclerosis	2.9e-05	0.000288	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	2.88e-05	0.000286	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	2.86e-05	0.000283	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	2.82e-05	0.00028	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	2.75e-05	0.000273	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	2.74e-05	0.000271	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.72e-05	0.000269	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	2.66e-05	0.000264	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.65e-05	0.000263	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	2.64e-05	0.000261	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—APOE—amyotrophic lateral sclerosis	2.53e-05	0.000251	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.5e-05	0.000247	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	2.49e-05	0.000247	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	2.44e-05	0.000242	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.4e-05	0.000238	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	2.32e-05	0.00023	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	2.25e-05	0.000223	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	2.19e-05	0.000217	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	2.17e-05	0.000215	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.09e-05	0.000208	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.07e-05	0.000205	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—APOE—amyotrophic lateral sclerosis	2.05e-05	0.000204	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.05e-05	0.000203	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.98e-05	0.000196	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.92e-05	0.000191	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	1.89e-05	0.000187	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	1.85e-05	0.000183	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.82e-05	0.00018	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	1.74e-05	0.000172	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.73e-05	0.000172	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.69e-05	0.000167	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—APOE—amyotrophic lateral sclerosis	1.58e-05	0.000157	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.56e-05	0.000155	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.43e-05	0.000142	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	1.43e-05	0.000142	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.41e-05	0.00014	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.35e-05	0.000134	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.25e-05	0.000124	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—APOE—amyotrophic lateral sclerosis	1.18e-05	0.000117	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.17e-05	0.000116	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.16e-05	0.000115	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.16e-05	0.000115	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.15e-05	0.000114	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.09e-05	0.000108	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.08e-05	0.000107	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.07e-05	0.000106	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.95e-06	9.86e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	9.42e-06	9.34e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.14e-06	9.06e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	8.88e-06	8.8e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	8.8e-06	8.73e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.09e-06	8.01e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.68e-06	7.61e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	7.52e-06	7.46e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.06e-06	6.99e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.46e-06	6.4e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.09e-06	6.03e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.03e-06	5.98e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	5.81e-06	5.75e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.16e-06	5.11e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.98e-06	3.94e-05	CbGpPWpGaD
